Checkmate Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CMPI and buy or sell other stocks, ETFs, and their options commission-free!About CMPI
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies.
CEOAlan Bash
CEOAlan Bash
Employees—
Employees—
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2015
Founded2015
Employees—
Employees—
CMPI Key Statistics
Market cap231.40M
Market cap231.40M
Price-Earnings ratio-3.60
Price-Earnings ratio-3.60
Dividend yield—
Dividend yield—
Average volume145.25K
Average volume145.25K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$10.50
52 Week high$10.50
52 Week low$2.00
52 Week low$2.00
Stock Snapshot
As of today, Checkmate Pharmaceuticals(CMPI) shares are valued at $10.50. The company's market cap stands at 231.4M, with a P/E ratio of -3.60.
During the trading day, Checkmate Pharmaceuticals(CMPI) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Checkmate Pharmaceuticals(CMPI) stock has reached 0, versus its average volume of 145.25K.
The stock's 52-week range extends from a low of $2.00 to a high of $10.50.
The stock's 52-week range extends from a low of $2.00 to a high of $10.50.
People also own
Based on the portfolios of people who own CMPI. This list is generated using Robinhood data, and it’s not a recommendation.